Nabriva Therapeutics plc (NBRV)の価格はいくらですか

Nabriva Therapeutics plc (NBRV)の価格は$0.63です

Nabriva Therapeutics plc (NBRV)の時価総額は何ですか

Nabriva Therapeutics plc (NBRV)の時価総額は$284.20Kです

Nabriva Therapeutics plc（NBRV）の株価履歴

Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.

年	パフォーマンス
2023	-62.69%
2022	-88.16%
2021	-77.92%
2020	-82.12%
2019	-3.21%
2018	-70.79%
2017	19.90%
2016	-48.03%
2015	0.00%

年

パフォーマンス

2023

-62.69%

2022

-88.16%

2021

-77.92%

2020

-82.12%

2019

-3.21%

2018

-70.79%

2017

19.90%

2016

-48.03%

2015

0.00%

企業	株価	変化率 1年%	国
Vertex Pharmaceuticals Incorporated VRTX.US	$517.18	32.51%	US
Argenx SE ARGX.US	$857.76	31.47%	NL
Lonza Group AG LONN.SW	$744.96	9.07%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.15%	KR
UCB S.A. UCB.BR	$259.89	14.81%	BE

企業

株価

変化率 1年%

国